Intrexon Corporation (XON) Rating Reiterated by Northland Securities

Northland Securities reissued their buy rating on shares of Intrexon Corporation (NYSE:XON) in a research report released on Friday morning. Northland Securities currently has a $21.00 price target on the biotechnology company’s stock.

Several other research analysts have also recently commented on the stock. Zacks Investment Research cut shares of Intrexon Corporation from a hold rating to a sell rating in a report on Thursday, July 13th. Bank of America Corporation decreased their target price on shares of Intrexon Corporation from $25.00 to $21.00 and set a neutral rating for the company in a report on Friday. Stifel Nicolaus raised their target price on shares of Intrexon Corporation from $39.00 to $57.00 and gave the stock a buy rating in a report on Friday. BidaskClub cut shares of Intrexon Corporation from a hold rating to a sell rating in a report on Friday, August 4th. Finally, JMP Securities reiterated an outperform rating and issued a $42.00 target price on shares of Intrexon Corporation in a report on Thursday, October 5th. Two equities research analysts have rated the stock with a sell rating, one has assigned a hold rating and five have assigned a buy rating to the company. The stock has a consensus rating of Hold and a consensus price target of $38.50.

Intrexon Corporation (XON) opened at $12.58 on Friday. Intrexon Corporation has a 12-month low of $10.25 and a 12-month high of $32.90. The company has a current ratio of 2.05, a quick ratio of 1.85 and a debt-to-equity ratio of 0.01.

WARNING: “Intrexon Corporation (XON) Rating Reiterated by Northland Securities” was first reported by Transcript Daily and is the property of of Transcript Daily. If you are reading this article on another site, it was copied illegally and republished in violation of U.S. and international copyright laws. The correct version of this article can be viewed at https://transcriptdaily.com/2017/11/14/intrexon-corporation-xon-rating-reiterated-by-northland-securities.html.

In related news, Director Robert B. Shapiro purchased 2,850 shares of Intrexon Corporation stock in a transaction dated Tuesday, August 22nd. The stock was acquired at an average cost of $17.50 per share, with a total value of $49,875.00. Following the completion of the transaction, the director now directly owns 43,157 shares of the company’s stock, valued at $755,247.50. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 56.30% of the stock is owned by corporate insiders.

A number of institutional investors and hedge funds have recently modified their holdings of XON. State Street Corp raised its position in Intrexon Corporation by 34.0% during the first quarter. State Street Corp now owns 2,707,242 shares of the biotechnology company’s stock valued at $53,664,000 after acquiring an additional 687,406 shares in the last quarter. First Trust Advisors LP raised its position in Intrexon Corporation by 32.5% during the second quarter. First Trust Advisors LP now owns 1,537,088 shares of the biotechnology company’s stock valued at $37,028,000 after acquiring an additional 376,780 shares in the last quarter. Vanguard Group Inc. raised its position in Intrexon Corporation by 5.6% during the first quarter. Vanguard Group Inc. now owns 4,286,362 shares of the biotechnology company’s stock valued at $84,954,000 after acquiring an additional 226,090 shares in the last quarter. Commonwealth Equity Services Inc raised its position in Intrexon Corporation by 660.7% during the third quarter. Commonwealth Equity Services Inc now owns 158,089 shares of the biotechnology company’s stock valued at $3,005,000 after acquiring an additional 137,307 shares in the last quarter. Finally, Credit Suisse AG raised its position in Intrexon Corporation by 273.7% during the first quarter. Credit Suisse AG now owns 183,555 shares of the biotechnology company’s stock valued at $3,638,000 after acquiring an additional 134,434 shares in the last quarter. 77.28% of the stock is currently owned by hedge funds and other institutional investors.

Intrexon Corporation Company Profile

Intrexon Corporation (Intrexon) forms collaborations to create biologically-based products and processes using synthetic biology. The Company’s domestic operations are in California, Florida, Maryland, and Virginia, and its primary international operations are in Belgium and Hungary. The Company designs, builds and regulates gene programs, which are deoxyribonucleic acid (DNA) sequences that consist of genetic components.

Analyst Recommendations for Intrexon Corporation (NYSE:XON)

Receive News & Ratings for Intrexon Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intrexon Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply